PTPRF and metabolic disease: We have conducted studies on the inhibition of human recombinant PTP1B, the most extensively described biological target for vanadium activity, as well as on highly homologous human tyrosine phosphatases, such as LAR, SHP1, and SHP2, which may have potential relevance in metabolic diseases [27,29].